Bellerophon Therapeutics Inc (NASDAQ:BLPH) Director Acquires $32,000.00 in Stock

Bellerophon Therapeutics Inc (NASDAQ:BLPH) Director Theodore T. Wang acquired 50,000 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was acquired at an average cost of $0.64 per share, for a total transaction of $32,000.00. Following the transaction, the director now owns 584,479 shares of the company’s stock, valued at approximately $374,066.56. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of BLPH traded up $0.01 during mid-day trading on Friday, hitting $0.64. The stock had a trading volume of 1,896 shares, compared to its average volume of 277,377. The firm has a market cap of $44.10 million, a PE ratio of -1.88 and a beta of -0.02. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.99 and a quick ratio of 2.99. Bellerophon Therapeutics Inc has a 52 week low of $0.47 and a 52 week high of $3.30.

Bellerophon Therapeutics (NASDAQ:BLPH) last issued its earnings results on Thursday, May 9th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.11. Sell-side analysts anticipate that Bellerophon Therapeutics Inc will post -0.21 earnings per share for the current fiscal year.

Several research firms have weighed in on BLPH. Zacks Investment Research raised Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Wednesday, May 15th. Maxim Group set a $3.00 price objective on Bellerophon Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 8th.

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc raised its stake in shares of Bellerophon Therapeutics by 2.5% in the third quarter. Vanguard Group Inc now owns 1,023,533 shares of the biotechnology company’s stock valued at $1,105,000 after buying an additional 25,300 shares during the period. Geode Capital Management LLC raised its stake in shares of Bellerophon Therapeutics by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 27,027 shares during the period. Sabby Management LLC bought a new stake in shares of Bellerophon Therapeutics in the first quarter valued at $202,000. Renaissance Technologies LLC raised its stake in shares of Bellerophon Therapeutics by 5.0% in the first quarter. Renaissance Technologies LLC now owns 1,317,676 shares of the biotechnology company’s stock valued at $860,000 after buying an additional 62,200 shares during the period. Finally, Arch Venture Corp bought a new stake in shares of Bellerophon Therapeutics in the first quarter valued at $631,000. Hedge funds and other institutional investors own 54.68% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Bellerophon Therapeutics Inc (NASDAQ:BLPH) Director Acquires $32,000.00 in Stock” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.themarketsdaily.com/2019/06/14/bellerophon-therapeutics-inc-nasdaqblph-director-acquires-32000-00-in-stock.html.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Further Reading: How Do Mutual Funds Work?

Insider Buying and Selling by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.